Company Beximco Pharmaceuticals Limited London S.E.

BXP

US0885792061

Pharmaceuticals

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for Beximco Pharmaceuticals Limited

EPS Revisions

Annual profits - Rate of surprise

Sector Other Pharmaceuticals

Delayed London S.E. Other stock markets 11:35:01 2024-06-24 EDT			5-day change	1st Jan Change
39.5 ^GBX	0.00%		+2.60%	-4.82%

04-30	EARNINGS AND TRADING: Software Circle & Beximco report higher revenue	AN
04-30	Beximco Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	CI

Beximco Pharmaceuticals Limited is a Bangladesh-based company which is a manufacturer of pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs). The Company is engaged in manufacturing and marketing of generic pharmaceutical formulation products covering a range of therapeutic categories. It offers products in different dosage forms, including Solid, Liquid, Cream and Ointment, Suppositories, Metered Dose Inhaler, Dry Powder Inhaler, Nasal Spray, Sterile, Lyophilized Injectable and Large Volume Intravenous Fluids. Besides formulation products, the Company also manufactures APIs and renders contract manufacturing services to other companies. Products of the Company are sold in domestic and international markets. The subsidiaries of the Company include Nuvista Pharma Limited (NPL), Synovia Pharma PLC (SPP), Beximco Pharma API Limited (BPAL).

Number of employees: 5,700

BDT in Million	2022	Weight	2023	Weight	Delta
Pharmaceutical Formulations and Active Pharmaceutical Ingredients 100.0 %	34,669	100.0 %	39,267	100.0 %	+13.26%

BDT in Million	2022	Weight	2023	Weight	Delta
Bangladesh 100.0 %	34,669	100.0 %	39,267	100.0 %	+13.26%

Managers	Title	Age	Since
Mohammad Ali Nawaz DFI	Director of Finance/CFO	61	89-12-31
Subodh Chandra Das CTO	Chief Tech/Sci/R&D Officer	-	-
Selina Akter CTO	Chief Tech/Sci/R&D Officer	-	-
S. M. Rabbur Reza COO	Chief Operating Officer	-	05-02-28
Mohammad Asad Ullah BRD	Director/Board Member	-	-
Mehboobul Haque PRN	Corporate Officer/Principal	-	-
M. A. Arshad Bhuiyan HRO	Human Resources Officer	-	-
Shawkat Haider PRN	Corporate Officer/Principal	-	-
Roksana Hassan AUD	Comptroller/Controller/Auditor	-	-
Shamim Momtaz PRN	Corporate Officer/Principal	-	06-12-31

Members of the board	Title	Age	Since
Salman Fazlur Rahman FOU	Founder	-	75-12-31
Ahmed Sohail Fasihur Rahman FOU	Founder	-	75-12-31
Iqbal Ahmed CEO	Chief Executive Officer	-	84-12-31
Osman Kaiser Chowdhury BRD	Director/Board Member	-	90-12-31
Abu Bakar Siddiqur Rahman BRD	Director/Board Member	-	92-12-31
Mohammad Asad Ullah BRD	Director/Board Member	-	-
Mamtaz Uddin Ahmed BRD	Director/Board Member	-	20-07-29
Quamrun Naher Ahmed BRD	Director/Board Member	64	20-11-29
Reem Shamsuddoha BRD	Director/Board Member	36	20-11-29
Mohammad Ibraheem H. Khan BRD	Director/Board Member	64	21-01-17

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	446,112,089	342,099,318 ( 76.68 %)	0	76.68 %

Name	Equities	%	Valuation
New Dacca Industries Ltd. 3.216 %	14,345,757	3.216 %	13 M p
Banor Capital Ltd. 0.007595 %	33,883	0.007595 %	31 487 p
Eurizon Capital SA 0.004538 %	20,244	0.004538 %	18 813 p

Name	Equities	%	Valuation
Tundra Fonder AB 0.2096 %	935,000	0.2096 %	458 318 p
eQ Varainhoito Oy 0.0828 %	369,467	0.0828 %	181 105 p

Beximco Pharmaceuticals Ltd.

19 Dhanmondi R/A Road No. 7

1205, Dhaka

+880 2 5861 1001

http://www.beximcopharma.com

address Beximco Pharmaceuticals Limited(BXP)

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

103.5 BDT

Average target price

177.5 BDT

Spread / Average Target

+71.50%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+52.70%	801B
NOVO NORDISK A/S	+41.58%	631B
JOHNSON & JOHNSON	-4.86%	359B
MERCK & CO., INC.	+21.96%	337B
ABBVIE INC.	+11.47%	305B
ASTRAZENECA PLC	+17.72%	245B
ROCHE HOLDING AG	+4.46%	231B
NOVARTIS AG	+13.13%	219B
AMGEN INC.	+10.46%	171B

Other Pharmaceuticals